Uploaded January 2024 | Updated September 2026, 1 week ago
Michael E Williams, MD
Professor, Department of Medicine
Transcript:
I'm a clinical investigator in the University of Virginia Comprehensive Cancer Center, and I'm so grateful and excited to be involved in a field where there's been such dramatic progress in treatment options and cures for so many patients with cancer and blood disease.
I'm Dr. Michael Williams. I'm a professor of medicine in the hematology oncology division and associate director for clinical affairs in the UVA, comprehends of Cancer Center.
My work is focused in lymphoma, specifically understanding the molecular underpinnings that drive these cancers and also employing and testing in clinical research, novel targeted agents and immunotherapies that are improving survival and cure while minimizing the traditional use of chemotherapy and radiation therapy.
Lymphoma therapy has really evolved rapidly in recent years so that we are no longer using nearly as much traditional chemotherapy. Instead, we're using targeted drugs which block a key pathway that the tumor cells depend upon, and also to use immunotherapeutics, which are engineered to activate a patient's own immune system or to deliver immunologic effect that destroys the tumor cells.
We can do this because we have such robust collaborators in the UVA Cancer Center laboratories and coming soon in the new Manning Institute.
Michael E Williams, MD
Professor, Department of Medicine
Transcript:
I'm a clinical investigator in the University of Virginia Comprehensive Cancer Center, and I'm so grateful and excited to be involved in a field where there's been such dramatic progress in treatment options and cures for so many patients with cancer and blood disease.
I'm Dr. Michael Williams. I'm a professor of medicine in the hematology oncology division and associate director for clinical affairs in the UVA, comprehends of Cancer Center.
My work is focused in lymphoma, specifically understanding the molecular underpinnings that drive these cancers and also employing and testing in clinical research, novel targeted agents and immunotherapies that are improving survival and cure while minimizing the traditional use of chemotherapy and radiation therapy.
Lymphoma therapy has really evolved rapidly in recent years so that we are no longer using nearly as much traditional chemotherapy. Instead, we're using targeted drugs which block a key pathway that the tumor cells depend upon, and also to use immunotherapeutics, which are engineered to activate a patient's own immune system or to deliver immunologic effect that destroys the tumor cells.
We can do this because we have such robust collaborators in the UVA Cancer Center laboratories and coming soon in the new Manning Institute.
